ヘパリン誘発性血小板減少の病原性におけるモノクローナル抗体
Jared Treverton1,2, Donald M Arnold2,3, Daniil G Ivanov4
1Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, ON, Canada.
The New England journal of medicine
|September 3, 2025
まとめ
ヘパリン誘発性血栓縮小 (HIT) の病原性抗体は,ポリクローンではなくモノクローンである. HIT患者でのこの発見は 病気のメカニズムと 診断と治療の進歩の可能性について 新たな洞察をもたらします
科学分野:
- 免疫学
- 血液学
- 分子生物学
背景:
- ヘパリン誘発性血小板減少症 (HIT) は,免疫媒介による血小板障害である.
- HITは,血小板因子4 (PF4) - ヘパリン複合体を標的とする抗体によって引き起こされます.
- 以前,HITはポリクローン免疫反応と考えられていたが,関連する疾患はクローン制限を示している.
研究 の 目的:
- ヘパリン誘発性血栓縮小 (HIT) の病原性抗体のクローナリティを調査する.
- HIT抗体がモノクローナルかポリクローナルかを決定する.
- HITの診断と治療への影響を理解する.
主な方法:
- 9人のHIT患者の血清から PF4ヘパリン玉を使用したアフィニティ浄化抗体
- 免疫固定電解と質量スペクトロメトリで抗体のクローナリティを評価した.
- 抗体結合と血小板活性化の評価は,酵素免疫測定とP-セレクチン発現測定を用いて行われました.
主要な成果:
- 全9人のHIT患者サンプルでは,PF4-ヘパリンに対する血小板活性化抗体が示されました.
- 免疫固定により,試料の67%でモノクローナル抗体が検出され,質量スペクトロメトリにより,すべての浄化された抗体でモノクローナリティが確認された.
- 精製された抗体は血小板を活性化し, 枯渇した血清は活動を失い, 病原性抗体の除去が確認されました.
結論:
- すべての研究されたHIT患者の病原性抗体は単一クローンであった.
- この発見はHITの病原性を明らかにする.
- 結果は,HITの診断と治療戦略の改善を示唆しています.
関連する概念動画
Anticoagulant Drugs: Low-Molecular-Weight Heparins
889
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
889
Hybridoma Technology
15.3K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
15.3K
Antibody Actions
1.3K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
1.3K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
644
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
644
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
Venous Thrombosis III: Interprofessional Care
22
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
22


